Durvalumab,Monalizumab,Oleclumab,Ceralasertib,DOCETAXEL,Savolitinib
AstraZeneca,Innate,Sanofi,Aventis,hutchmed
['thanks', 'biomarker', 'nsclc', 'alkaline', 'ca,022,i', 'ca,022,001', 'sclc', 'pioneer', 'lba5', 'marker ']
can we predict which pt will get benefited from io drugs in nsclc using genomic signatures? the pioneer study . subgroup analysis. #esmoasia22 
Oncology care , to give or not to give chemo , data analysis , oncology pharamocovigilance , enthusiastic critic, twitts are not twists